Zafgen Cuts Deal With Argenta

Luke Timmerman1/29/09

Zafgen, the Cambridge, MA-based developer of drugs to shrink fat tissue, said today it has formed a partnership with Harlow, UK-based Argenta Discovery. Argenta, a contract research firm, will assist with the development of one of Zafgen’s experimental treatments for obesity. Earlier this week, we profiled this company’s quest to pioneer a new method of treatment which cuts off blood flow to fat tissue. Financial terms of the new partnership weren’t disclosed.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.